Endocrinology
60 articles on Endocrinology, researched and written by the Shotlee Editorial Team from primary sources.
Study Links GLP-1 Medications To Rare Vision Issue
New research indicates a possible association between GLP-1 medications, commonly prescribed for type 2 diabetes and weight management, and a rare but serious vision issue. This article explores the study's findings, potential implications, and expert recommendations.
6 min read
Mounjaro's Impact on Food Cravings: A Case Study
A groundbreaking case study involving deep brain activity recordings has shed light on how tirzepatide, known as Mounjaro and Zepbound, impacts the brain's reward center and its connection to food cravings and loss of control eating.
8 min read
Ozempic, Wegovy, and Mounjaro May Alter Taste: How Food Flavor Changes Can Impact Cravings
Discover how incretin-based therapies like Ozempic, Wegovy, and Mounjaro might be changing the way you experience food. This article delves into new research linking altered taste perception to reduced appetite and cravings, offering insights for patients and clinicians.
8 min read
The Next Ozempic: A 4-in-1 Breakthrough for Lasting Weight Loss
While Ozempic and similar GLP-1 agonists have revolutionized weight management, new research from Tufts University is exploring a novel 4-in-1 peptide that targets four hormone receptors for potentially greater efficacy and fewer side effects, moving closer to the gold standard of bariatric surgery.
6 min read
Most People Who Stop GLP-1 Drugs Like Ozempic Eventually Restart Treatment
A recent study presented at ENDO 2026 sheds light on the patterns of GLP-1 medication use for type 2 diabetes, revealing that while many patients stop treatment, a substantial number later restart, suggesting a more cyclical rather than permanent discontinuation.
7 min read
Semaglutide Linked to Fewer Bone Fractures Despite Greater Weight Loss
Discover how semaglutide, a popular GLP-1 medication, shows a surprising benefit in a recent study, potentially reducing bone fracture risk even as it aids in substantial weight loss for individuals with type 2 diabetes.
7 min read
Beyond Weight Loss: How GLP-1s Like Ozempic May Reshape Your Inner World
GLP-1 medications have revolutionized weight loss, but are they also changing how we feel, think, and connect? This article delves into the emerging 'Ozempic Personality' and the science behind potential mood and behavioral shifts.
9 min read
Ozempic, Wegovy & Mounjaro: What Your Bones & Joints Need to Know
Millions are experiencing significant weight loss with GLP-1 medications. But what happens to your bones, joints, and muscles as the pounds drop? An orthopedic surgeon shares crucial insights.
7 min read
Tirzepatide vs. Semaglutide: Which Weight Loss Peptide Reigns Supreme?
The landscape of medical weight loss has been revolutionized by potent peptide therapies. Among the most talked-about are semaglutide and tirzepatide, the active ingredients in popular medications like Wegovy, Ozempic, Zepbound, and Mounjaro. But when it comes to shedding pounds, which one truly takes the lead? This article delves into the science, the studies, and the practical differences to help you understand their comparative effectiveness.
7 min read
Wegovy Arrives in Jordan: A New Era for Weight Management
Novo Nordisk has officially launched Wegovy®️ (semaglutide 2.4 mg) in Jordan, marking a significant advancement in the country's approach to tackling the growing challenge of excess weight and its associated health risks.
7 min read
GLP-1s and Menopause: Expert Warns of Accelerated Bone Loss Risk
The collision of rapid weight loss driven by GLP-1 medications like Wegovy and Mounjaro with the natural bone density decline of menopause creates a significant, under-discussed risk for women's skeletal health.
6 min read
Semaglutide Linked to Stronger Bones in Type 2 Diabetes Patients
A landmark study suggests semaglutide may protect bone strength while aiding weight loss, offering new hope for diabetes management and bone health.
8 min read
Ozempic & Wegovy: Surprising Bone Health Benefit Uncovered
While GLP-1 agonists like Ozempic and Wegovy are celebrated for weight loss and blood sugar control, a recent study suggests a surprising benefit: improved bone health and a reduced risk of fractures in adults with Type 2 diabetes.
7 min read
Semaglutide and Tirzepatide: The Reality of Stopping and Restarting
A groundbreaking analysis of diabetes medication patterns reveals that stopping isn't always permanent. Discover which drugs have the best retention rates and how insurance impacts access.
7 min read
Ozempic and Testosterone: Does Weight Loss Drive Sperm Quality Gains?
A comprehensive review of clinical trials suggests that GLP-1 medications may offer reproductive benefits for men with obesity-related low testosterone, potentially surpassing traditional hormone replacement therapies.
7 min read
Cagrilintide + Semaglutide: A Promising Dual Approach for Type 2 Diabetes
New research presented at the American Diabetes Association meeting highlights the potential of combining cagrilintide, an amylin receptor agonist, with semaglutide for improved glycemic control in adults with type 2 diabetes.
7 min read
CagriSema Breakthrough: New Dual Therapy Delivers Major Weight Loss in Diabetes Trials
Explore the groundbreaking REIMAGINE trial results for CagriSema, a novel dual-agonist therapy showing superior glycemic control and weight loss in type 2 diabetes patients.
7 min read
Beyond GLP-1s: Unlocking Better Diabetes Control with Korlym
For individuals struggling with difficult-to-control type 2 diabetes and weight management, even powerful GLP-1 medications might not be enough. New research highlights the significant role of hypercortisolism and the promising potential of Korlym in optimizing treatment outcomes.
6 min read
Wegovy, Mounjaro & Your Libido: How GLP-1s Reshape Desire
GLP-1 medications have transformed weight management and diabetes care, but their effects extend beyond the scale. Many users report surprising changes to their libido and sexual function. This article delves into why these powerful drugs can either boost or dampen your sex drive, offering insights from leading medical experts.
9 min read
Wegovy Pill Arrives: A New Era for Oral Weight Management in the UAE
Novo Nordisk's revolutionary Wegovy pill (oral semaglutide) is set to transform weight management in the UAE. Discover the details of its early access launch, clinical benefits, and how it integrates into advanced care pathways.
7 min read
Ozempic, Wegovy: New Insights Into Brain Receptors Could Revolutionize Dosing
Millions are experiencing transformative weight loss with GLP-1 agonists like Ozempic and Wegovy. However, many encounter plateaus. Groundbreaking research from the NIH is shedding light on why this happens within the brain's appetite control centers, potentially paving the way for more effective and personalized treatment plans.
6 min read
Beyond the 'Bridal Glow': The Real Story of Mounjaro & Weight Loss
As 'Mounjaro brides' become a trend, an endocrinologist unpacks the medical realities, risks, and ethical concerns surrounding using powerful weight-loss medications for cosmetic pre-wedding transformations.
9 min read
GLP-1s, Hormones, and Weight Loss: What Women Need to Know
Many women starting GLP-1 therapies experience significant weight loss, only to find their menopausal symptoms—like hot flashes and sleep issues—intensify. This phenomenon is often overlooked because rapid fat loss directly interacts with the body's declining estrogen production, creating a complex hormonal shift that many prescribers are not trained to address.
6 min read
Retatrutide's Triumph: Lilly's Triple Agonist Redefines Weight Loss Potential
Eli Lilly's retatrutide is making waves in the weight loss landscape. This comprehensive look delves into its Phase III results, comparing it to existing treatments and exploring its potential impact on obesity management.
6 min read
GLP-1 Medications and Supplement Needs: What You Should Know
As GLP-1 medications gain popularity for weight loss and diabetes management, understanding their impact on nutrient absorption is crucial. This article explores the link between these powerful drugs and the rising demand for supplements, offering insights from medical professionals and research.
6 min read
GLP-1 Drugs and Vision Loss: Understanding NAION Lawsuits
Recent lawsuits are raising serious questions about the potential for GLP-1 medications, widely used for diabetes and weight loss, to cause a rare but devastating eye condition known as NAION, leading to permanent vision loss. This article delves into the allegations, scientific evidence, and ongoing legal proceedings.
6 min read
The Next Wave of Weight Loss: Understanding Oral GLP-1 Therapy
The landscape of chronic weight management is rapidly evolving beyond injectable GLP-1 medications. New research, including trials for the oral, non-peptide drug orforglipron, suggests a future where highly effective weight loss treatment is as simple as taking a daily pill, potentially overcoming barriers of cost and injection fatigue.
6 min read
GLP-1 Agonists: A New Frontier in Liver Disease Treatment
GLP-1 receptor agonists, renowned for their impact on type 2 diabetes and obesity, are now emerging as powerful allies in the fight against liver diseases like MASH and alcohol-associated liver disease. Discover how these groundbreaking medications are reshaping hepatology.
6 min read
GLP-1s, Liver Health, and Digestive Innovations: A Medical Update
This comprehensive update delves into groundbreaking research on GLP-1 receptor agonists and their impact on liver health, alongside crucial developments in inflammatory bowel disease (IBD) management and innovative approaches to digestive symptom relief. Discover how cutting-edge science is shaping patient care and explore practical implications for managing chronic conditions.
7 min read
Pharmac Funding for Wegovy: What NZ Patients Need to Know
New Zealand's Pharmac funding agency has moved semaglutide (Wegovy) to its investment list. Here is what this means for eligibility, costs, and access.
8 min read
Oral GLP-1s for Weight Loss Maintenance: A New Frontier
A groundbreaking study reveals that switching to an oral GLP-1 medication like orforglipron can help individuals maintain a significant portion of their weight loss achieved with injectable therapies, offering a new avenue for long-term obesity management.
6 min read
PCOS Renamed PMOS: A New Era for Endocrine Health
Polycystic Ovary Syndrome (PCOS), a condition affecting millions of women, is undergoing a significant renaming to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change aims to better reflect the condition's complex interplay with endocrine and metabolic systems, potentially improving diagnosis and treatment.
8 min read
Sustainable Weight Loss: Expert Tips for Lasting Results
Achieving sustainable weight loss is a journey, not a race. This comprehensive guide offers expert advice on nutrition, exercise, and mindset to help you build healthy habits for life.
10 min read
GLP-1 Pills for Weight Loss: 8 Key Insights Before You Begin
GLP-1 medications are now available as pills for weight loss, offering a needle-free alternative. This comprehensive guide explores what you need to know before starting, including efficacy, absorption, side effects, and lifestyle considerations.
12 min read
Online GLP-1 Programs: Revolutionizing Medically Supervised Weight Loss
Discover the seismic shift in obesity medicine as online GLP-1 programs leverage telehealth and advanced medications like semaglutide and tirzepatide to provide accessible, medically supervised weight loss solutions.
11 min read
GLP-1 Agonists: Age Limits & Serious Risks of Weight Loss Drugs
This comprehensive guide delves into the critical considerations surrounding GLP-1 agonists for weight loss, addressing common concerns about age limits, potential risks, and practical advice for patients.
7 min read
AOD-9604: Unpacking the Metabolic Signals of a Growth Hormone Fragment
AOD-9604, a fragment of human growth hormone, is being studied for its potential to selectively influence lipid metabolism and energy balance, offering a unique lens into peptide signaling.
9 min read
Oral Semaglutide Shows Promise for Pediatric Type 2 Diabetes
Novo Nordisk recently unveiled compelling topline results from the PIONEER TEENS trial, suggesting that oral semaglutide could become the first oral GLP-1 Receptor Agonist (RA) therapy approved for children and adolescents managing Type 2 Diabetes (T2D). This development addresses a significant gap in pediatric endocrinology, offering a potentially more accessible treatment option.
6 min read
Eli Lilly's Oral GLP-1: A Strong Start Amidst Weight Loss Drug Hype
Eli Lilly's groundbreaking oral GLP-1, Foundayo, is demonstrating a promising launch, exceeding initial expectations and hinting at a significant expansion of the weight loss and diabetes management market. Discover the latest insights and what it means for patients and the industry.
7 min read
GLP-1 Medications: Miracle Drug, Wellness Trend, or Vanity?
GLP-1 medications have surged from diabetes treatment to mainstream wellness. This article examines their medical benefits, potential downsides, and the evolving societal perception of weight loss.
7 min read
Oral GLP-1 Drugs: A New Era for Weight Management in India
The landscape of weight management in India is on the cusp of a significant transformation with the advent of oral GLP-1 therapies. Driven by innovation from Chinese pharmaceutical companies and the impending patent expirations of existing treatments, these new pill-based options promise greater accessibility and affordability, fundamentally reshaping how obesity and metabolic disorders are addressed.
7 min read
New AI-Discovered Molecule Offers Potential Ozempic/Wegovy Alternative
A groundbreaking discovery using artificial intelligence has identified a naturally occurring molecule, BRP, that targets the brain's appetite center, potentially offering a new and improved alternative for weight management compared to current GLP-1 medications.
7 min read
Why Mounjaro is Having a Moment: Content Creator's Weight Loss Story
Content creator Aishwarya Mohanraj's candid video about dropping from 74kg to 52kg in six months on Mounjaro has spotlighted the injectable drug. Amid PCOS and hypothyroidism challenges, her story shifts focus from Ozempic hype. But experts warn: pair it with lifestyle changes or risk weight regain.
5 min read
Cheaper Generic Semaglutide in India: Experts Warn Against Quick-Fix Use
Cheaper generic semaglutide is transforming access to weight loss and diabetes treatment in India, priced at just Rs750 per weekly injection. However, experts caution against 'quick-fix' use without medical oversight, highlighting risks like 40% muscle loss from lean mass. Discover clinical evidence from STEP-1 and SELECT trials and why structured care is essential.
5 min read
GLP-1 Weight Loss Consistent Across Race, Age, BMI—But Not Sex
GLP-1 receptor agonists like semaglutide show consistent weight loss efficacy across diverse groups, but a notable sex difference emerges: women average 10.9% body weight loss versus 6.8% for men. This JAMA meta-analysis reassures clinicians while highlighting areas for further research. Experts explain why this matters for personalized obesity care.
5 min read
GLP-1 Weight-Loss Drugs Face Bone Health Risks in Older Adults
Emerging research is raising questions about GLP-1 weight-loss drugs like Ozempic and Wegovy, showing a potential link to bone loss and fractures in older adults. A major study in the Journal of Clinical Endocrinology & Metabolism found higher fragility fracture risks among seniors on these medications. Experts stress monitoring and preventive steps to balance benefits with bone protection.
5 min read
Semaglutide Generics Set for One-Fourth Price After Patent Expiry
Semaglutide prices in India are poised for a dramatic drop to one-fourth of current levels following patent expiry on March 20. Generics from seven companies like Sun Pharma and Zydus Lifesciences will make Ozempic and Wegovy alternatives more accessible for diabetes and obesity management. Experts highlight improved adherence but warn of misuse risks.
5 min read
Mounjaro Shortage Harms Patients Amid Diet Craze: Supply Crisis
A surge in dieting demand has triggered shortages of Mounjaro's 5mg starting dose, making it hard for metabolic disease patients to access treatment. Clinics in Seoul report instability until late March, as non-reimbursed status leaves supply unmanaged. Patients like Mr. A face halted therapy despite proven benefits for diabetes control and weight loss.
6 min read
GLP-1 Drugs Linked to Skin Pain: New Reports of Dysesthesia & Allodynia
Emerging reports suggest GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) may trigger unusual sensory side effects, including painful skin sensitivity known as dysesthesia and allodynia. A new case series provides critical insights for patients and clinicians.
7 min read
Burn Slim Exposed: Real Users Reveal GLP-1 Mimetic Effects
Burn Slim Capsules are gaining attention as a natural GLP-1 mimetic alternative to prescription drugs like semaglutide. Real users report dramatic appetite changes, consistent fat loss up to 22 pounds in 12 weeks, and sustained results without muscle loss or loose skin. Backed by studies on its four key ingredients, this guide exposes the science and user truths.
6 min read
What Happens After Stopping GLP-1 Drugs Like Ozempic? UK Study Findings
A new Cambridge study reveals that after stopping GLP-1 drugs like Ozempic and Wegovy, patients regain nearly 60% of lost weight within a year, with appetite returning rapidly. Researchers modeled long-term trends showing about 75% regain over time, emphasizing the need for lifestyle support. This comprehensive guide breaks down the findings and what they mean for patients.
6 min read
GLP-1 Drugs Like Ozempic Raise Bone and Tendon Injury Risks, Study Suggests
New research reveals GLP-1 medications like Ozempic may significantly elevate risks of bone disorders and tendon injuries. Analyzing nearly 150,000 patients, the study found 30% higher osteoporosis rates and 50% increased tendon rupture risks over five years. Experts urge bone density monitoring amid these findings.
5 min read
Glenmark to Launch Affordable Semaglutide, Joining Indian Peers
Glenmark Pharmaceuticals is gearing up to launch affordable versions of semaglutide, the blockbuster GLP-1 drug for diabetes and obesity, later this month. This move intensifies competition among Indian drugmakers like Sun Pharma and Dr Reddy's following the March 21 patent expiry. With prices potentially half those of innovators, millions of patients stand to gain better access.
5 min read
GLP-1 Activates KATP Channels in Coronary Pericytes for Cardioprotection
A new study in Nature Communications uncovers how GLP-1 activates ATP-sensitive potassium (KATP) channels in coronary pericytes, providing a novel cardioprotective mechanism through brain-gut-heart signaling. This discovery shifts focus from cardiomyocytes to the microvascular role of pericytes in enhancing myocardial blood flow. Understand the implications for GLP-1 receptor agonists in heart disease treatment.
7 min read
GLP-1 Overdoses in Kids: Risks, Symptoms & Prevention Guide
Poison control calls for GLP-1 medications have skyrocketed, with children accidentally injecting drugs like Mounjaro leading to severe vomiting and hospitalization. This guide breaks down the risks, what happens in an overdose, and proven prevention strategies. Stay informed to protect your family while benefiting from these powerful weight loss tools.
4 min read
GLP-1 News 2025: Safety Alerts, Fakes & Breakthroughs
GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound now make up over 7% of U.S. prescriptions, fueling weight loss trends but raising safety concerns. From FDA warnings on sharing pens to charges over fake drugs, here's what patients need to know. Discover emerging research and tools to manage your therapy safely.
4 min read
GLP-1 Nutrition Boosters: Pharma & Startup Innovations
GLP-1 medications like Ozempic and Wegovy are transforming weight management, but side effects like gut issues and muscle loss demand smart support. Nutrition and pharma startups are stepping up with targeted innovations to enhance results and minimize risks. Learn how binding proteins, protein enzymes, and novel inhibitors create a comprehensive ecosystem for long-term success.
4 min read
GLP-3s, Monthly Pens: Next Obesity Drugs Leap in 2026
GLP-1 drugs like Ozempic and Mounjaro have revolutionized weight loss, and the next wave—GLP-3s such as retatrutide—promises even greater results. Eli Lilly's phase 3 trial revealed up to 28.7% body weight loss in 48 weeks. Discover monthly injections, oral pills, and emerging indications for 2026.
3 min read
Ozempic Weight Loss Boom: Rising Legal Risks
Semaglutide-based Ozempic has become a weight loss sensation beyond diabetes treatment. Yet, over 1,800 US lawsuits signal serious risks including gastroparesis, bowel issues, and vision loss from NAION. UK and Irish prescribers face growing negligence exposure.
2 min read
Pharmaceutical firms compensate Indiana physicians for discussing GLP-1 medications, data reveals
An analysis of public data shows that pharmaceutical firms paid over $533,000 to Indiana healthcare professionals in 2024 for speaking about GLP-1 medications. The funds covered travel and expenses for conferences. Experts discuss potential influences on prescribing practices, while doctors defend the educational value.
6 min read